DocVaz Medical Billing provides specialized hematology medical billing services for hematologists, hematology-oncology practices, infusion centers, and blood disorder clinics across the United States. From complex chemotherapy and biologic drug billing to coagulation disorder coding and specialty pharmacy prior authorizations, DocVaz builds a revenue cycle process designed around the unique financial and regulatory demands of hematology care.
| 97.6% Clean claim rate on specialty drug billing | 20+ Years in hematology & oncology billing | 48 Hrs Average prior authorization turnaround | 50 States served nationwide |
Hematology sits at the intersection of laboratory medicine, infusion therapy, oncology, and chronic disease management. Practices treat everything from routine anemia and clotting disorders to blood cancers and rare genetic conditions, often within the same clinic day. That range creates a billing environment with far more moving parts than standard primary or specialty care, and it is one of the most frequently under-billed or denied specialties in the country when handled by a generalist billing team.
Hematology practices regularly administer high-cost biologics, monoclonal antibodies, clotting factor concentrates, and chemotherapy agents. Each drug requires the correct HCPCS J-code, accurate units-of-billing calculation, and National Drug Code (NDC) reporting. A single unit-of-measure error on a factor VIII or immunoglobulin claim can result in thousands of dollars in denied reimbursement.
Many hematology practices purchase specialty drugs directly and bill payers after administration — the 'buy-and-bill' model. This requires precise inventory-to-claim reconciliation, documentation of drug wastage using the JW modifier, and close monitoring of Average Sales Price (ASP) reimbursement rates, which change quarterly.
Biologics, growth factors, and specialty infusions used in hematology almost always require prior authorization, step-therapy documentation, and periodic re-authorization. Delayed or denied authorizations directly stall both patient care and practice cash flow.
A single hematology visit may combine an evaluation and management (E/M) service, laboratory draw, infusion administration, and injectable drug billing — each requiring correct modifier use (25, 59, JW, JZ) to avoid bundling denials or duplicate-billing rejections.
Conditions such as sickle cell disease, hemophilia, myelodysplastic syndromes, and chronic anemia require ongoing, cyclical treatment. Billing teams must track treatment calendars, cumulative dosing, and payer-specific frequency limits across months or years of care.
DocVaz Medical Billing supports the full revenue cycle for hematology and hematology-oncology practices, from patient intake through final reimbursement.
Accurate HCPCS J-code assignment, NDC-level reporting, and units-of-billing calculation for chemotherapy agents, monoclonal antibodies, clotting factor products, immunoglobulins, and iron replacement therapies.
Inventory-to-claim matching, ASP rate tracking, and drug wastage documentation to ensure every vial and every billed unit is accounted for and reimbursed correctly.
End-to-end prior authorization submission and follow-up for specialty biologics and infusions, including payer-specific step-therapy documentation and periodic re-authorization tracking.
Specialized coding for hemophilia, von Willebrand disease, and other clotting disorders, including factor replacement therapy billing and coordination with hemophilia treatment center (HTC) reimbursement structures.
Billing support for leukemia, lymphoma, myeloma, and myelodysplastic syndrome treatment, including chemotherapy administration coding (96401–96549), infusion sequencing, and combination-therapy claim structuring.
Correct CPT coding for complete blood counts, peripheral smears, coagulation panels, bone marrow biopsies, and molecular/genetic testing associated with blood disorder diagnosis.
Root-cause analysis for specialty drug denials, medical necessity appeals, and payer escalation for high-dollar hematology claims that are disproportionately vulnerable to underpayment.
Pre-treatment insurance verification and benefits investigation for high-cost infusions ensure that patient responsibility and payer coverage are confirmed before therapy begins.
Enrollment and re-validation support with Medicare, Medicaid, and commercial payers, including specialty pharmacy network credentialing for infusion-based hematology practices.
Hematology billing depends on precise code selection across evaluation, laboratory, infusion, and diagnosis categories. DocVaz coders stay current with CMS and AMA updates across the following code families:
Code Family | Examples Managed by DocVaz |
CPT (Infusion) | 96365–96368 (IV infusion), 96401–96417 (chemotherapy administration) |
CPT (Laboratory) | 85025 (CBC with differential), 85610 (PT), 85730 (PTT), 85097 (bone marrow smear) |
HCPCS (Drugs) | J-codes for factor concentrates, immunoglobulins, monoclonal antibodies, and iron therapies |
Modifiers | 25, 59, JW (drug wastage), JZ (no wastage), GA/GZ (ABN-related) |
ICD-10 (Blood Disorders) | D50–D64 (anemias), D65–D69 (coagulation defects), D66/D67 (hemophilia) |
ICD-10 (Malignancies) | C81–C96 (lymphomas, leukemias, myeloma) |
A structured, sequential process built around the high dollar value and regulatory sensitivity of hematology claims:
Insurance Verification & Benefits Investigation
Prior Authorization Management
Documentation & Coding Review
Charge Entry & Drug Reconciliation
Claim Submission
Payer Adjudication Tracking
Denial Management & Appeals
Payment Posting & Financial Reporting
DocVaz Medical Billing focuses on the specific financial pressure points for hematology practices: high drug costs, heavy prior-authorization loads, and dense coding requirements.
There are multiple billing companies, but here are some reasons why practices across the United States trusted DocVaz:
Request a hematology billing audit and identify where your practice may be losing revenue on specialty drugs, infusion claims, or prior authorization delays. Whether you need our services for a personal project, a business, or a special event, our team is here to help. Contact us today to discuss your needs, ask questions, and receive a personalized quote. We look forward to providing reliable service and helping you achieve the best possible results.
Hematology billing involves high-cost specialty drugs, complex infusion coding, frequent prior authorizations, and buy-and-bill reimbursement — all of which require coders trained specifically in infusion and specialty pharmacy billing rather than general E/M coding.
Yes. DocVaz manages the full prior authorization and step-therapy documentation process for biologics, clotting factor products, and infusion therapies used in hematology care.
Yes. DocVaz reconciles purchased drug inventory against billed units, tracks ASP reimbursement rates, and documents drug wastage using the correct JW and JZ modifiers to protect practice margins.
Yes. DocVaz has specific experience billing for hemophilia treatment centers and coagulation disorder clinics, including factor replacement therapy claims.
Yes. DocVaz codes and bills chemotherapy administration, combination infusion therapy, and related oncology services for blood cancer treatment.
DocVaz supports hematology and hematology-oncology providers in all 50 states, with billing workflows adapted to state-specific Medicaid and payer rules.